Worth reading
20Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
0
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
8th and 9th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
発行済株式総数
Exercise ratio for the month under review: 0.00% for Series 8 and 0.00% for Series 9. Dilution from the issuance of new shares as a percentage of shares issued and outstanding: Not disclosed
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Series 8: ¥2,757 (1 May 2026 to 29 May 2026); Series 9: ¥3,192 (1 May 2026 to 29 May 2026). Details of the adjustment provisions and the adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Series 8: total number issued and remaining unexercised rights: Not disclosed; exercised during the month under review: 0; remaining unexercised rights at month-end: 2,340 (234,000 shares). Series 9: total number issued and remaining unexercised rights: Not disclosed; exercised during the month under review: 0; remaining unexercised rights at month-end: 727 (72,700 shares)
Procedures under the Corporate Code of Conduct
Reported compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Similar Transactions.
Most recent equity financing
Timing 7 April 2022 / Type 8th and 9th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | 8th and 9th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Dilution Rate | Exercise ratio for the month under review: 0.00% for Series 8 and 0.00% for Series 9. Dilution from the issuance of new shares as a percentage of shares issued and outstanding: Not disclosed |
| Total number of issued shares | 2,762,100 shares (as of the end of the month preceding the month under review) → Not disclosed |
| Exercise price | Series 8: ¥2,757 (1 May 2026 to 29 May 2026); Series 9: ¥3,192 (1 May 2026 to 29 May 2026). Details of the adjustment provisions and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Series 8: total number issued and remaining unexercised rights: Not disclosed; exercised during the month under review: 0; remaining unexercised rights at month-end: 2,340 (234,000 shares). Series 9: total number issued and remaining unexercised rights: Not disclosed; exercised during the month under review: 0; remaining unexercised rights at month-end: 727 (72,700 shares) |
| Procedures under the Corporate Code of Conduct | Reported compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Similar Transactions. |
| Most recent equity financing | Timing 7 April 2022 / Type 8th and 9th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) / Amount Not disclosed |
Items this document does not state (21)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for May 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.